A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Study acronym: EMERALD-2
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study completion date changed from estimate of Aug 2026 to Sep 21, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 9 of 102 sites
  2. Results first posted: Dec 15, 2025
    • Primary endpoint revised
    • Enrollment target: 282 to 280
    • Secondary endpoint revised
    v33
  3. Study sites revised (102)v32
  4. Lead sponsor: Morphic Therapeutic, Inc to Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
    • Study sites: 125 to 102
    • Start date: Oct 31, 2022 to Nov 21, 2022
    v31
  5. Enrollment target: estimated 280 to confirmed 282
    • Primary completion date changed from estimate of Dec 2024 to Nov 28, 2024
    v30
Show 28 earlier versionsHide 28 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 137 to 125
    • Primary completion date: May 2025 to Dec 2024
    • Study completion date: Jul 2025 to Aug 2026
    v29
  2. Site details revised at 2 of 137 sitesv28
  3. Site details revised at 1 of 137 sitesv27
  4. Study sites: 24 to 137v26
  5. Site details revised at 1 of 24 sitesv25
  6. Study sites: 23 to 24v24
  7. Site details revised at 3 of 23 sitesv23
  8. Study sites: 22 to 23v22
  9. Study sites: 21 to 22v21
  10. Study sites: 20 to 21v20
  11. Study sites: 19 to 20v19
  12. Study sites: 18 to 19v18
  13. Study sites: 17 to 18v17
  14. Study sites: 18 to 17v16
  15. Study sites: 17 to 18v15
  16. Re-verified, no change to tracked fieldsv14
  17. Study sites: 16 to 17v13
  18. Study sites: 15 to 16v12
  19. Study sites: 14 to 15v11
  20. Study sites: 13 to 14v10
  21. Study sites: 12 to 13v9
  22. Study sites: 11 to 12v8
  23. Study sites: 10 to 11v7
  24. Study sites: 9 to 10v6
  25. Study sites: 8 to 9v5
  26. Study sites: 7 to 8v4
  27. Study sites: 2 to 7v3
  28. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Ulcerative Colitis
627 trials monitored
See 40 trials at risk
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Trial Details
NCT Number NCT05611671
Lead Sponsor Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Conditions
(from sponsor)		 Inflammatory Bowel Diseases, Colitis, Ulcerative
Related terms Colitis, Ulcerative, Inflammatory Bowel Diseases
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov